JP2015520151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520151A5 JP2015520151A5 JP2015511669A JP2015511669A JP2015520151A5 JP 2015520151 A5 JP2015520151 A5 JP 2015520151A5 JP 2015511669 A JP2015511669 A JP 2015511669A JP 2015511669 A JP2015511669 A JP 2015511669A JP 2015520151 A5 JP2015520151 A5 JP 2015520151A5
- Authority
- JP
- Japan
- Prior art keywords
- edema
- compound
- compound according
- disease
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 208000006752 brain edema Diseases 0.000 claims 15
- 206010048962 Brain oedema Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 206010021143 Hypoxia Diseases 0.000 claims 8
- 230000007954 hypoxia Effects 0.000 claims 8
- 206010030113 Oedema Diseases 0.000 claims 7
- 102000010637 Aquaporins Human genes 0.000 claims 6
- 108010063290 Aquaporins Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 150000003839 salts Chemical group 0.000 claims 4
- 208000009447 Cardiac Edema Diseases 0.000 claims 3
- 206010021036 Hyponatraemia Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000031225 myocardial ischemia Diseases 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010019196 Head injury Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000005486 microgravity Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 2
- 208000032253 retinal ischemia Diseases 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 206010025130 Lupus encephalitis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000034388 Mountain sickness acute Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 206010033712 Papilloedema Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010038886 Retinal oedema Diseases 0.000 claims 1
- 206010041549 Spinal cord compression Diseases 0.000 claims 1
- 206010063036 Spinal cord oedema Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 208000005735 Water intoxication Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 208000018315 acute mountain sickness Diseases 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000008081 blood perfusion Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000002296 eclampsia Diseases 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 201000008284 inappropriate ADH syndrome Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 201000011195 retinal edema Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
- 0 CC(C)(C(C1)=CC(*C(C=C(CCC(*)=*)OI(*)(*)=O)=O)=CC1C(F)(F)F)F Chemical compound CC(C)(C(C1)=CC(*C(C=C(CCC(*)=*)OI(*)(*)=O)=O)=CC1C(F)(F)F)F 0.000 description 2
- UQRLOIYSRFRJKL-UHFFFAOYSA-N OC(c(cc(cc1)Cl)c1OCC(C1O)(C1O)O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound OC(c(cc(cc1)Cl)c1OCC(C1O)(C1O)O)Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1 UQRLOIYSRFRJKL-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644268P | 2012-05-08 | 2012-05-08 | |
| US61/644,268 | 2012-05-08 | ||
| US201261651778P | 2012-05-25 | 2012-05-25 | |
| US61/651,778 | 2012-05-25 | ||
| US201361799606P | 2013-03-15 | 2013-03-15 | |
| US61/799,606 | 2013-03-15 | ||
| PCT/US2013/040194 WO2013169939A2 (en) | 2012-05-08 | 2013-05-08 | New methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017210529A Division JP6570597B2 (ja) | 2012-05-08 | 2017-10-31 | 新規方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520151A JP2015520151A (ja) | 2015-07-16 |
| JP2015520151A5 true JP2015520151A5 (enExample) | 2016-06-23 |
| JP6238969B2 JP6238969B2 (ja) | 2017-11-29 |
Family
ID=49551452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511669A Active JP6238969B2 (ja) | 2012-05-08 | 2013-05-08 | 新規方法 |
| JP2017210529A Active JP6570597B2 (ja) | 2012-05-08 | 2017-10-31 | 新規方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017210529A Active JP6570597B2 (ja) | 2012-05-08 | 2017-10-31 | 新規方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9994514B2 (enExample) |
| EP (1) | EP2846787B1 (enExample) |
| JP (2) | JP6238969B2 (enExample) |
| KR (1) | KR102200176B1 (enExample) |
| CN (2) | CN104602682B (enExample) |
| AU (2) | AU2013259526B2 (enExample) |
| BR (1) | BR112014027983B1 (enExample) |
| CA (1) | CA2872012C (enExample) |
| ES (1) | ES2699646T3 (enExample) |
| IL (1) | IL235512B (enExample) |
| MX (1) | MX363473B (enExample) |
| RU (1) | RU2671495C2 (enExample) |
| WO (1) | WO2013169939A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| CA2929821A1 (en) * | 2013-11-06 | 2015-05-14 | Aeromics, Inc. | 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits |
| US20180042873A1 (en) * | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
| JP2018500388A (ja) * | 2014-11-18 | 2018-01-11 | ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー |
| CZ2014915A3 (cs) * | 2014-12-16 | 2016-02-24 | Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové | Substituovaný derivát kyslíkatých kyselin fosforu, jeho použití a farmaceutický přípravek ho obsahující |
| US10246733B2 (en) | 2015-06-04 | 2019-04-02 | Case Western University | Assay and method for quantitating carbonic anhydrase activity and assessing red blood hemolysis |
| CN105030747B (zh) * | 2015-07-03 | 2017-11-17 | 厦门大学 | 氯硝柳胺在制备防治近视药物中的应用 |
| CN109562137A (zh) | 2015-09-01 | 2019-04-02 | 第波生物公司 | 用于治疗与异常炎性反应有关的病况的方法和组合物 |
| KR20230173224A (ko) | 2016-05-13 | 2023-12-26 | 에어로믹스, 인코포레이티드 | 결정 |
| CA3024610A1 (en) | 2016-05-18 | 2017-11-23 | David J. Augeri | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer |
| WO2018053807A1 (zh) * | 2016-09-23 | 2018-03-29 | 深圳市中医院 | 氯硝柳胺乙醇胺盐在制备1型糖尿病药物中的应用 |
| TWI631944B (zh) * | 2016-10-14 | 2018-08-11 | 長庚大學 | 氯硝柳胺及其衍生物的用途 |
| EP3624885B1 (en) | 2017-05-19 | 2026-02-18 | Trudell Medical International Inc. | Positive expiratory pressure device |
| JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α１−アンチキモトリプシンを含むバイオマーカー |
| US10945995B2 (en) * | 2017-09-26 | 2021-03-16 | Deha, Llc | Compositions and methods for channelopathy disorders-targeting fluid movement across membranes |
| CN108203719A (zh) * | 2017-12-26 | 2018-06-26 | 吉林医药学院 | 用于治疗视神经脊髓炎的小分子化合物及其高通量筛选方法 |
| USD903097S1 (en) | 2018-05-18 | 2020-11-24 | Trudell Medical International | Mask |
| USD874064S1 (en) | 2018-05-18 | 2020-01-28 | Trudell Medical International | Mask |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| USD893806S1 (en) | 2018-11-09 | 2020-08-18 | Trudell Medical Internationl | Mask and shroud |
| USD902947S1 (en) * | 2019-03-25 | 2020-11-24 | Apple Inc. | Electronic device with graphical user interface |
| CN112107568B (zh) | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| CN110790787B (zh) * | 2019-11-12 | 2022-06-14 | 广东药科大学 | 一类水溶性前药、其制备方法及其作为药物的用途 |
| US10980756B1 (en) | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| EP4192442A4 (en) * | 2020-08-05 | 2025-03-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising an aquaporin inhibiter and manufacturing process therefor |
| CN116139116A (zh) * | 2023-03-30 | 2023-05-23 | 中南大学湘雅医院 | 氯硝柳胺在抑制急性肝衰竭中的应用 |
| WO2025075479A1 (ko) * | 2023-10-04 | 2025-04-10 | 이화여자대학교 산학협력단 | 아쿠아포린 4 억제제의 심방세동 치료 용도 |
| EP4559520A1 (en) | 2023-11-21 | 2025-05-28 | Origenis GmbH | Novel aqp4 inhibitors |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE615511A (enExample) | 1961-03-25 | |||
| NL292958A (enExample) | 1962-05-29 | 1900-01-01 | ||
| GB8809205D0 (en) | 1988-04-19 | 1988-05-25 | Nye P C G | Treatment of oedema |
| US5137871A (en) * | 1989-07-28 | 1992-08-11 | Regents Of The University Of California | Treatment to reduce edema for brain and musculature injuries |
| DE4010536A1 (de) | 1990-04-02 | 1991-10-10 | Boehringer Mannheim Gmbh | Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure |
| US5137817A (en) | 1990-10-05 | 1992-08-11 | Amoco Corporation | Apparatus and method for electroporation |
| US5486530A (en) | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
| DE4113820A1 (de) | 1991-04-27 | 1992-10-29 | Boehringer Mannheim Gmbh | Verwendung von torasemid zur behandlung von hirnoedemen |
| US5741671A (en) | 1991-12-12 | 1998-04-21 | The Johns Hopkins University | Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1) |
| US5858702A (en) | 1991-12-13 | 1999-01-12 | The Johns Hopkins University | Isolation, cloning and expression of transmembrane water channel Aquaporin 5 (AQP5) |
| US5519035A (en) * | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
| US20060167110A1 (en) * | 1995-01-13 | 2006-07-27 | Blume Cherly D | Methods for treating cerebrovascular disease by administering desmethylselegiline |
| EP0886471A4 (en) | 1996-11-18 | 2002-07-17 | Emisphere Tech Inc | METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES |
| WO1999007382A1 (en) | 1997-08-06 | 1999-02-18 | Smithkline Beecham Corporation | Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases |
| US5905090A (en) | 1998-04-29 | 1999-05-18 | Italfarmaco S.P.A. | Analogues of the active metabolite of leflunomide |
| CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
| US6500809B1 (en) * | 1999-11-12 | 2002-12-31 | Neuron Therapeutics, Inc. | Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| ES2211460T3 (es) * | 1999-12-10 | 2004-07-16 | Pfizer Inc. | Compuestos de 1,4-dihidropiridina sustituidos con un heteroalrilo de 5 miembros como antagonistas de la bradiquinina. |
| CN101849953B (zh) | 2000-12-18 | 2012-04-25 | 株式会社医药分子设计研究所 | 炎症性细胞因子产生游离抑制剂 |
| US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
| EP2438913B1 (en) | 2002-03-20 | 2020-05-06 | University of Maryland, Baltimore | A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling |
| US20060019958A1 (en) | 2002-06-05 | 2006-01-26 | Susumu Muto | Immunity-related protein kinase inhibitors |
| JPWO2003103648A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| WO2003103647A1 (ja) | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | Ａｐ−１及びｎｆａｔ活性化阻害剤 |
| AU2003242118B2 (en) * | 2002-06-06 | 2008-09-11 | Institute Of Medicinal Molecular Design, Inc | O-substituted hydroxyaryl derivatives |
| CN1658872B (zh) | 2002-06-06 | 2010-09-22 | 株式会社医药分子设计研究所 | 抗过敏药 |
| EP1535609A4 (en) | 2002-06-10 | 2009-01-07 | Inst Med Molecular Design Inc | Nf-kb activation inhibitors |
| CA2488974A1 (en) | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of cancer |
| EP1555018A4 (en) | 2002-06-11 | 2009-01-07 | Inst Med Molecular Design Inc | MEANS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| KR20050019739A (ko) * | 2002-06-11 | 2005-03-03 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 신경변성질환 치료제 |
| CA2492593A1 (en) | 2002-07-15 | 2004-01-22 | Myriad Genetics, Inc. | Compounds, compositions, and methods employing same |
| WO2004068928A2 (en) | 2003-02-06 | 2004-08-19 | Uutech Limited | Bradykinin b2 receptor antagonist peptide from amphibian skin |
| US20080125488A1 (en) * | 2003-05-01 | 2008-05-29 | Leverve Xavier M | Lactate Containing Pharmaceutical Composition and Uses Thereof |
| KR20060054308A (ko) | 2003-07-16 | 2006-05-22 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 피부 색소침착의 치료제 |
| AU2004279855A1 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
| US8467876B2 (en) * | 2003-10-15 | 2013-06-18 | Rmx, Llc | Breathing disorder detection and therapy delivery device and method |
| WO2005039556A1 (ja) | 2003-10-29 | 2005-05-06 | Institute Of Medicinal Molecular Design. Inc. | 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬 |
| EP1691817A2 (en) | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
| CN101043891A (zh) | 2004-09-18 | 2007-09-26 | 巴尔的摩马里兰大学 | 靶向NCCa－ATP通道的治疗剂及其使用方法 |
| CA2580606A1 (en) | 2004-09-18 | 2006-03-30 | University Of Maryland, Baltimore | Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| US7601745B2 (en) * | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| EP1835909A2 (en) | 2005-01-04 | 2007-09-26 | Novartis AG | Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation |
| TWI462745B (zh) | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
| WO2007084464A2 (en) | 2006-01-17 | 2007-07-26 | The University Of North Carolina At Chapel Hill | Water channel blockers and methods of use thereof |
| JP4273235B2 (ja) | 2006-06-01 | 2009-06-03 | 国立大学法人 新潟大学 | アクアポリン４阻害薬 |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| US20100056444A1 (en) | 2006-10-12 | 2010-03-04 | Sven Martin Jacobson | Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors |
| EP2086329B1 (en) | 2006-10-26 | 2014-07-23 | The Arizona Board of Regents on behalf of the University of Arizona | Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance |
| US9316633B2 (en) | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| US20080171719A1 (en) | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
| WO2008067382A2 (en) | 2006-11-28 | 2008-06-05 | Alcon Research, Ltd. | Rnai-mediated inhibition of aquaporin 4 for treatment of iop-related conditions |
| CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
| US20120183600A1 (en) | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| CN101631859B (zh) * | 2007-01-16 | 2017-10-13 | Ipintl有限责任公司 | 用于治疗代谢综合征的新组合物 |
| WO2008098160A1 (en) | 2007-02-09 | 2008-08-14 | University Of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
| BRPI0807918A2 (pt) | 2007-02-17 | 2017-05-16 | Harvard College | composições e método para preservação de tecido |
| WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| EP2167107B1 (en) | 2007-06-22 | 2016-12-14 | University of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
| WO2009006555A2 (en) | 2007-07-02 | 2009-01-08 | Yu, Ming | Methods, composition, targets for combinational cancer treatments |
| US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
| AU2008314979A1 (en) | 2007-10-23 | 2009-04-30 | Institute Of Medicinal Molecular Design, Inc. | Inhibitor of PAI-1 production |
| CN101932308B (zh) | 2007-12-04 | 2014-11-05 | 治疗医药股份有限公司 | 改良的配制剂和用于冻干的方法及由此提供的冻干物 |
| GB0724340D0 (en) * | 2007-12-13 | 2008-01-30 | Univ Dundee | Novel Therapeutic Agents |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| US8211882B2 (en) * | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
| WO2009139925A1 (en) * | 2008-05-16 | 2009-11-19 | Panacea Pharmaceuticals, Inc. | Methods for the treatment of brain edema |
| EP2326318A4 (en) | 2008-09-16 | 2012-05-23 | Univ Maryland | SUR1 HEMMER FOR THERAPEUTIC PURPOSES |
| US20120010178A1 (en) | 2008-10-21 | 2012-01-12 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
| GB0823366D0 (en) | 2008-12-22 | 2009-01-28 | Uni I Oslo | Synthesis |
| CA2749575C (en) * | 2009-01-12 | 2016-05-03 | Versitech Limited | Compounds and uses thereof for treating inflammation and modulating immune responses |
| US20120039805A1 (en) * | 2009-02-20 | 2012-02-16 | Pangea Biosciences, Inc. | Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample |
| CN102883742B (zh) * | 2010-03-10 | 2014-09-24 | 佛罗里达大学研究基金会有限公司 | 用松弛素调节水孔蛋白 |
| KR20200054319A (ko) | 2010-07-19 | 2020-05-19 | 바이오젠 체사피크 엘엘씨 | 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법 |
| EP2598145A1 (en) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
| US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| WO2012125749A2 (en) | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
| DK2717883T3 (en) | 2011-05-02 | 2017-04-24 | Stichting Vumc | PROTECTION AGAINST ENDOTELIAL BARRIER DYSFUNCTION BY INHIBITION OF THE TYROSINKINASE ABL RELATED GENES (ARG) |
| RU2461375C1 (ru) | 2011-05-19 | 2012-09-20 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Способ комбинированного лечения больных местно-распространенным раком желудка |
| WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| WO2013152313A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| US9452973B2 (en) | 2012-05-04 | 2016-09-27 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
| WO2013169939A2 (en) | 2012-05-08 | 2013-11-14 | Aeromics, Llc | New methods |
| WO2015037659A1 (ja) | 2013-09-13 | 2015-03-19 | 株式会社医薬分子設計研究所 | 水溶液製剤及びその製造方法 |
| CA2929821A1 (en) | 2013-11-06 | 2015-05-14 | Aeromics, Inc. | 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate formulations and kits |
| JP6463580B2 (ja) | 2013-12-13 | 2019-02-06 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ |
| US20180042873A1 (en) | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
| ES2927482T3 (es) | 2015-05-29 | 2022-11-07 | Univ Maryland | Métodos para reducir o prevenir el daño de la íntima causado por la estimulación mecánica de las células endoteliales |
| IL258509B2 (en) | 2015-10-07 | 2023-04-01 | Biogen Chesapeake Llc | Methods for treating injuries or conditions related to edema in the central nervous system |
| KR20230173224A (ko) | 2016-05-13 | 2023-12-26 | 에어로믹스, 인코포레이티드 | 결정 |
| KR102646250B1 (ko) | 2016-07-29 | 2024-03-11 | 레메디 파마슈티칼즈, 인크. | Sur1-trpm4 통로 저해제를 이용하는 의학적 치료 방법 |
| EP4192442A4 (en) | 2020-08-05 | 2025-03-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising an aquaporin inhibiter and manufacturing process therefor |
-
2013
- 2013-05-08 WO PCT/US2013/040194 patent/WO2013169939A2/en not_active Ceased
- 2013-05-08 AU AU2013259526A patent/AU2013259526B2/en active Active
- 2013-05-08 JP JP2015511669A patent/JP6238969B2/ja active Active
- 2013-05-08 CA CA2872012A patent/CA2872012C/en active Active
- 2013-05-08 ES ES13788050T patent/ES2699646T3/es active Active
- 2013-05-08 BR BR112014027983-7A patent/BR112014027983B1/pt active IP Right Grant
- 2013-05-08 US US14/398,947 patent/US9994514B2/en active Active
- 2013-05-08 MX MX2014013639A patent/MX363473B/es unknown
- 2013-05-08 EP EP13788050.6A patent/EP2846787B1/en active Active
- 2013-05-08 RU RU2014148984A patent/RU2671495C2/ru active
- 2013-05-08 KR KR1020147033957A patent/KR102200176B1/ko active Active
- 2013-05-08 CN CN201380033198.7A patent/CN104602682B/zh active Active
- 2013-05-08 CN CN201811415090.5A patent/CN109512805B/zh active Active
-
2014
- 2014-11-05 IL IL235512A patent/IL235512B/en active IP Right Grant
-
2015
- 2015-06-27 US US14/752,839 patent/US9573885B2/en active Active
-
2017
- 2017-10-31 JP JP2017210529A patent/JP6570597B2/ja active Active
-
2018
- 2018-05-14 AU AU2018203357A patent/AU2018203357C1/en active Active
- 2018-05-17 US US15/982,644 patent/US11084778B2/en active Active
-
2021
- 2021-07-26 US US17/443,361 patent/US11873266B2/en active Active
-
2023
- 2023-12-12 US US18/537,093 patent/US12503425B2/en active Active